115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
    Meeting Abstract

    Ho, A. L.; Bowles, D. W.; Even, C.; Hao, D.; Kang, H.; Metcalf, R.; Muzaffar, J.; Oliva, M.; Perez, C. A.; Popovtzer, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
    Meeting Abstract

    Catenacci, D. V.; Liao, C. Y.; Maron, S.; Solomon, B. J.; Mahipal, A.; Johnson, M. L.; Carbone, D.; Henick, B. S.; Johnson, B.; Roychowdhury, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
    Meeting Abstract

    Vergote, I. B.; Monk, B. J.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S.; Collins, D. C.; Mirza, M. R.; O'Malley, D.; Gennigens, C.; Pignata, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
    Meeting Abstract

    Colombo, N.; Lorusso, D.; Casado Herráez, A.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Floquet, A.; Monk, B. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Cohn, A. L.; Brose, M. S.; DiSimone, C.; Cao, A.; Suttner, L.; Loboda, A.; Cristescu, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
    Meeting Abstract

    Colombo, N.; Nguyen, D. D.; Fleming, G. F.; Grisham, R. N.; Lorusso, D.; Van Gorp, T.; Oaknin, A.; Pashova, H. I.; Grauer, A.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
    Meeting Abstract

    Rosenberg, J. E.; Galsky, M. D.; Balar, A. V.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Srinivas, S.; Drakaki, A.; Javery, A.; Nelson, B.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Rini, B. I.; Plimack, E. R.; Powles, T. B.; Voss, M. H.; Gurney, H. P.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Choueiri, T. K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Porta, C. G.; Motzer, R.; Ejzykowicz, F.; Blum, S. I.; Hamilton, M.; May, J. R.; Huo, S.; Kral, P.; Ivanescu, C.; Choueiri, T. K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save